International audienceBackground: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and identify unmet needs in IPF treatment practice. Methods: Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain, and the UK participated in an online questionnaire designed to collect information on IPF treatment patterns in patients under their care. Patients were categorized as treated (received approved antifibrotics) or untreated (did not receive app...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung functi...
Objective: The authors aim to evaluate the challenges faced by each stakeholder for Idiopathic pulmo...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicin...
Background: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicin...
AbstractIdiopathic pulmonary fibrosis (IPF) is a rare, chronic and ultimately fatal disease for whic...
BACKGROUND: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
Background Idiopathic pulmonary fibrosis (IPF) is a complex disease with a highly variable clinical ...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
BackgroundCurrently, two disease-modifying antifibrotic drugs are indicated for the treatment of idi...
Background: For patients with idiopathic pulmonary fibrosis (IPF), there is limited real-world data ...
Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis(IPF) and has b...
Abstract Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lu...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung functi...
Objective: The authors aim to evaluate the challenges faced by each stakeholder for Idiopathic pulmo...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicin...
Background: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicin...
AbstractIdiopathic pulmonary fibrosis (IPF) is a rare, chronic and ultimately fatal disease for whic...
BACKGROUND: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
Background Idiopathic pulmonary fibrosis (IPF) is a complex disease with a highly variable clinical ...
Introduction: Pulmonary fibrosis (PF) and its most common form, idiopathic pulmonary fibrosis (IPF),...
BackgroundCurrently, two disease-modifying antifibrotic drugs are indicated for the treatment of idi...
Background: For patients with idiopathic pulmonary fibrosis (IPF), there is limited real-world data ...
Background: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis(IPF) and has b...
Abstract Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lu...
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung functi...
Objective: The authors aim to evaluate the challenges faced by each stakeholder for Idiopathic pulmo...
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, ou...